title: Is Kaposi's sarcoma occurring at higher CD4 cell counts over the course of the HIV epidemic?
abstract: We evaluated longitudinal rates of Kaposi's sarcoma and trends in CD4 cell counts at the time of Kaposi's sarcoma diagnosis during the HIV epidemic (1985-2008). Although rates of Kaposi's sarcoma have decreased, cases are now occurring at higher CD4 cell counts over time, with more than one-third of cases diagnosed in 2002-2008 occurring at CD4 cell counts of at least 350 cells/μl. These data support future studies evaluating the impact of highly active antiretroviral therapy initiation at higher CD4 cell counts to further reduce Kaposi's sarcoma.
authors.affiliation: Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA. nancy.crum@med.navy.mil
authors.forename: Nancy F
authors.initials: NF
authors.lastname: Crum-Cianflone
authors.forename: Katherine Huppler
authors.initials: KH
authors.lastname: Hullsiek
authors.forename: Anuradha
authors.initials: A
authors.lastname: Ganesan
authors.forename: Amy
authors.initials: A
authors.lastname: Weintrob
authors.forename: Jason F
authors.initials: JF
authors.lastname: Okulicz
authors.forename: Brian K
authors.initials: BK
authors.lastname: Agan
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology* / Q000276:immunology; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D058872:Epidemics; D005260:Female; D015497:HIV-1; D006801:Humans; D008297:Male; D012514:Sarcoma, Kaposi / Q000453:epidemiology* / Q000276:immunology; D019562:Viral Load; D055815:Young Adult
references.citation: Cancer. 2004 Jun 15;100(12):2644-54
references.pmid: 15197808
references.citation: J Clin Oncol. 2005 Feb 20;23(6):1253-60
references.pmid: 15718323
references.citation: Clin Infect Dis. 2004 Dec 15;39(12):1852-5
references.pmid: 15578411
references.citation: Ann Intern Med. 2008 May 20;148(10):728-36
references.pmid: 18490686
references.citation: JAMA. 1992 Apr 1;267(13):1798-805
references.pmid: 1347573
references.citation: N Engl J Med. 2008 Jan 31;358(5):535-6; author reply 536
references.pmid: 18234764
references.citation: J Acquir Immune Defic Syndr. 2009 Dec;52(5):611-22
references.pmid: 19770804
references.citation: J Clin Oncol. 2007 Jun 1;25(16):2230-5
references.pmid: 17470847
references.citation: AIDS. 1998 May 7;12(7):F45-9
references.pmid: 9619797
references.citation: J Acquir Immune Defic Syndr. 1999 Oct 1;22(2):209-10
references.pmid: 10843538
references.citation: AIDS. 2006 Aug 1;20(12):1645-54
references.pmid: 16868446
references.citation: MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
references.pmid: 1361652
references.citation: N Engl J Med. 2007 Sep 27;357(13):1352-3
references.pmid: 17898112
references.citation: AIDS. 2009 Jan 2;23(1):41-50
references.pmid: 19050385
references.citation: J Int Assoc Physicians AIDS Care (Chic). 2009 Sep-Oct;8(5):279-85
references.pmid: 19721098
references.citation: AIDS. 2007 Mar 30;21(6):775
references.pmid: 17413703
references.citation: J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):40-7
references.pmid: 18667932
references.citation: Cancer. 2003 Dec 1;98(11):2440-6
references.pmid: 14635079
references.citation: Ann Intern Med. 1999 Oct 5;131(7):502-6
references.pmid: 10507958